Schreiber Taylor 4

4 · Shattuck Labs, Inc. · Filed May 13, 2026

AI-generated summary of this filing

Updated May 13, 2026

Shattuck Labs (STTK) CEO Taylor Schreiber Receives Award, Exercises Warrant

What Happened

Taylor Schreiber, CEO of Shattuck Labs (STTK), acquired 25,610 shares on May 12, 2026 at $1.08 per share for a reported total of $27,777 (transaction code A — grant/award or other acquisition). On the same date the reporting person also recorded an exercise/conversion of a derivative (transaction code M) covering 25,610 shares (derivative disposition).
In plain terms: Schreiber received 25,610 common shares and a related derivative (warrant) position was exercised/converted the same day. This is an acquisition by an insider (generally viewed as a bullish signal relative to a sale), not a sale.

Key Details

Transaction date: May 12, 2026; Form filed May 13, 2026 (timely).
Share acquisition: 25,610 shares @ $1.08 = $27,777.
Derivative action: 25,610 shares listed as an exercise/conversion of a derivative (no separate exercise price shown on the provided excerpt).
Shares owned after transaction: not specified in the provided filing excerpt.
Footnotes of note:
- F1: These shares and accompanying warrants were originally issued in a private placement that closed Aug 25, 2025; combined price per share and accompanying warrant in that placement was $0.8677.
- F2: The warrants are exercisable after public announcement of certain Phase 1 clinical trial data and planned Phase 2 design. The filing's exercise entry indicates a conversion/exercise event occurred on May 12, 2026.

Context

The filing shows an acquisition plus the exercise/conversion of a derivative (warrant). For retail investors: an insider acquiring shares is typically more informative than routine sales, but filings alone do not reveal the insider's motive.
No indication in the provided excerpt that shares were immediately sold (no cashless/market sale reported).

Form 4

Period: 2026-05-12

DirectorChief Executive Officer

Transactions

Award
Common Stock
2026-05-12$1.08/sh+25,610$27,777→ 122,222 total
Exercise/Conversion
Warrants (Right to Buy)
[F1][F2]
2026-05-12−25,610→ 0 total
Exercise: $1.08→ Common Stock (25,610 underlying)

Holdings

Footnotes (2)

[F1]On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
[F2]The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Signature

/s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber|2026-05-13

1 file